Accuray announces receipt of FDA 510(k) Clearance for new CyberKnife M6 Series with heightened efficiency.
M2 EQUITYBITES-November 2, 2012-Accuray announces receipt of FDA 510(k) Clearance for new CyberKnife M6 Series with heightened efficiency(C)2012 M2 COMMUNICATIONS http://www.m2.com
Radiation oncology company Accuray Incorporated (Nasdaq:ARAY) said on Thursday that it has received 510(k) clearance from the US Food and Drug Administration (FDA) for its new CyberKnife M6 Series with expanded clinical capabilities, reduced treatment times and an enhanced patient experience.
The company's new CyberKnife M6 FIM and FM Systems, which features the InCise Multileaf Collimator, combines the benefits of beam shaping with the flexibility of non-isocentric, non-coplanar delivery offering unmatched clinical capabilities and expanding the number of patients eligible for treatment.
This new approved InCise Multileaf Collimator was designed specifically for stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT) treatments, giving the system the capability to extend its radiosurgical accuracy into a broader field of applications, meeting radiosurgery and radiotherapy needs.
With the addition of the InCise Multileaf Collimator, the CyberKnife M6 Series can be used to treat large and irregular tumors more efficiently with excellent dose gradients, according to the company.
((Comments on this story may be sent to email@example.com))
|Printer friendly Cite/link Email Feedback|
|Publication:||M2 EquityBites (EQB)|
|Date:||Nov 2, 2012|
|Previous Article:||DLM gets takeover approaches for operating units.|
|Next Article:||Corning Incorporated acquires BD Discovery Labware business, expanding llife sciences product portfolio & geographic reach.|